185 related articles for article (PubMed ID: 3019702)
21. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
Bauer B; Lorenz H; Zahlten R
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
[TBL] [Abstract][Full Text] [Related]
22. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
Schnaper HW
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S128-30. PubMed ID: 1725021
[TBL] [Abstract][Full Text] [Related]
23. [Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].
Unger T; Moursi MG; Lebrun C; Ganten D; Lang RE
Arch Mal Coeur Vaiss; 1986 Jun; 79(6):971-4. PubMed ID: 3026275
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
[TBL] [Abstract][Full Text] [Related]
25. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.
Witte PU; Walter U
Am J Cardiol; 1987 Apr; 59(10):115D-120D. PubMed ID: 3034018
[TBL] [Abstract][Full Text] [Related]
26. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
[TBL] [Abstract][Full Text] [Related]
27. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
28. Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure.
Crozier IG; Ikram H; Nicholls MG; Jans S
Am J Cardiol; 1987 Apr; 59(10):155D-163D. PubMed ID: 3034025
[TBL] [Abstract][Full Text] [Related]
29. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.
Janka HU; Nuber A; Mehnert H
Arzneimittelforschung; 1990 Apr; 40(4):432-5. PubMed ID: 2141472
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
Mroczek WJ
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S147-9. PubMed ID: 1725028
[TBL] [Abstract][Full Text] [Related]
31. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
Becker RH; Baldes L; Treudler M
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S35-9. PubMed ID: 2474099
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
33. Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.
de Graeff PA; Kingma JH; Dunselman PH; Wesseling H; Lie KI
Am J Cardiol; 1987 Apr; 59(10):164D-170D. PubMed ID: 3034026
[TBL] [Abstract][Full Text] [Related]
34. [Long-term blood pressure measurement for evaluating the first dose response of captopril and ramipril in patients with a stimulated renin system].
Lüders S; Schrader J; Schoel G; Ruschitzka F; Scheler F
Z Kardiol; 1992; 81 Suppl 2():41-4. PubMed ID: 1387500
[TBL] [Abstract][Full Text] [Related]
35. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
Burris JF
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
[TBL] [Abstract][Full Text] [Related]
36. Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.
Mauersberger H; Witte PU
Lancet; 1985 Mar; 1(8427):517-8. PubMed ID: 2857878
[No Abstract] [Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
Gerckens U; Grube E; Mengden T; Sigel H; Wagner WL; Lahn T; Irmisch R; Metzger H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S49-51. PubMed ID: 2474102
[TBL] [Abstract][Full Text] [Related]
38. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
39. [Ambulatory multicenter study of Triatec (ramipril). Observations concerning the lessons of the trial for the realization of future trials and for the management of hypertensive patients].
Battaglia C; Gallet M; Carré A
Rev Prat; 1990 Jun; 40(18 Suppl):45-7. PubMed ID: 2143598
[No Abstract] [Full Text] [Related]
40. Global and regional hemodynamic effects of ramipril in congestive heart failure.
Crozier IG; Ikram H; Nicholls MG; Jans S
J Cardiovasc Pharmacol; 1989 Nov; 14(5):688-93. PubMed ID: 2481181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
